Skip to main content
SpringerLink
Log in

FDA: boxed warning removed for varenicline, bupropion

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • FDA. FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. Internet Document : 16 Dec 2016. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm532221.htm

    Google Scholar 

  • 1. Varenicline: FDA committee recommends removing warning. 1620: 6, 24 Sep 2016

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

FDA: boxed warning removed for varenicline, bupropion. Reactions Weekly 1633, 5 (2017). https://doi.org/10.1007/s40278-017-24276-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-24276-6

Search

Navigation